
AuId,1389051172
now_work_for,1283280774
History_Afflication,
harvard medical school,1987-2016
brigham and women s hospital,1991-2016
None,1981-2016

Fields,

Field_Name,medicine
label_color,#9400D3


Field_Name,diabetes mellitus
label_color,rgb(92, 184, 92)


Field_Name,myocardial infarction
label_color,rgb(92, 184, 92)

first_page_year,1981
now_year,2016
Author_Name,paul m ridker
total_CC,45380
first author paper,

Publish Journal,n engl j med
Publish Year,2009
Cited Num,3651
Title,C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women


Publish Journal,n engl j med
Publish Year,2009
Cited Num,3561
Title,Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men


Publish Journal,n engl j med
Publish Year,2009
Cited Num,2838
Title,Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein


Publish Journal,acc current journal review
Publish Year,2009
Cited Num,2318
Title,Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events


Publish Journal,circulation
Publish Year,2000
Cited Num,1418
Title,Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men


Publish Journal,circulation
Publish Year,2003
Cited Num,1392
Title,C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events An 8-Year Follow-Up of 14 719 Initially Healthy American Women


Publish Journal,n engl j med
Publish Year,2009
Cited Num,1387
Title,C-Reactive Protein Levels and Outcomes after Statin Therapy


Publish Journal,circulation
Publish Year,2003
Cited Num,1339
Title,Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention


Publish Journal,acc current journal review
Publish Year,2009
Cited Num,1161
Title,A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women


Publish Journal,circulation
Publish Year,1998
Cited Num,1155
Title,Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy Women


Publish Journal,acc current journal review
Publish Year,2009
Cited Num,1034
Title,Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events


Publish Journal,circulation
Publish Year,1999
Cited Num,955
Title,Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein


Publish Journal,circulation
Publish Year,2001
Cited Num,905
Title,High-Sensitivity C-Reactive Protein Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease


Publish Journal,jama
Publish Year,2007
Cited Num,898
Title,Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.


Publish Journal,lancet
Publish Year,1998
Cited Num,839
Title,Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men


Publish Journal,circulation
Publish Year,1998
Cited Num,817
Title,Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels


Publish Journal,jama
Publish Year,2001
Cited Num,791
Title,Novel Risk Factors for Systemic Atherosclerosis: A Comparison of C-Reactive Protein, Fibrinogen, Homocysteine, Lipoprotein(a), and Standard Cholesterol Screening as Predictors of Peripheral Arterial Disease


Publish Journal,circulation
Publish Year,1999
Cited Num,742
Title,Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.


Publish Journal,circulation
Publish Year,1998
Cited Num,721
Title,C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction


Publish Journal,n engl j med
Publish Year,2009
Cited Num,647
Title,Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.


Publish Journal,circulation
Publish Year,1998
Cited Num,633
Title,Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease


Publish Journal,circulation
Publish Year,1998
Cited Num,627
Title,Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.


Publish Journal,circulation
Publish Year,2000
Cited Num,573
Title,Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction


Publish Journal,lancet
Publish Year,2009
Cited Num,517
Title,Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial


Publish Journal,acc current journal review
Publish Year,2009
Cited Num,482
Title,Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism


Publish Journal,lancet
Publish Year,1993
Cited Num,453
Title,Endogenous tissue-type plasminogen activator and risk of myocardial infarction


Publish Journal,circulation
Publish Year,2008
Cited Num,444
Title,C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction The Reynolds Risk Score for Men


Publish Journal,jama
Publish Year,2005
Cited Num,428
Title,Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.


Publish Journal,circulation
Publish Year,2004
Cited Num,409
Title,Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?


Publish Journal,jama
Publish Year,1993
Cited Num,391
Title,A prospective study of lipoprotein(a) and the risk of myocardial infarction.


Publish Journal,circulation
Publish Year,2001
Cited Num,364
Title,Soluble P-Selectin and the Risk of Future Cardiovascular Events


Publish Journal,circulation
Publish Year,1999
Cited Num,350
Title,Hormone Replacement Therapy and Increased Plasma Concentration of C-Reactive Protein


Publish Journal,jama
Publish Year,1997
Cited Num,342
Title,ETHNIC DISTRIBUTION OF FACTOR V LEIDEN IN 4047 MEN AND WOMEN. IMPLICATIONS FOR VENOUS THROMBOEMBOLISM SCREENING


Publish Journal,circulation
Publish Year,2001
Cited Num,330
Title,Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia


Publish Journal,j amer coll cardiol
Publish Year,2007
Cited Num,317
Title,C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.


Publish Journal,circulation
Publish Year,2004
Cited Num,310
Title,Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores


Publish Journal,circulation
Publish Year,2004
Cited Num,299
Title,Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events


Publish Journal,circulation
Publish Year,2003
Cited Num,293
Title,Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Rationale and Design of the JUPITER Trial


Publish Journal,circulation
Publish Year,1993
Cited Num,259
Title,Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.


Publish Journal,amer heart j
Publish Year,2011
Cited Num,253
Title,Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)


Publish Journal,lancet
Publish Year,2012
Cited Num,230
Title,Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial


Publish Journal,lancet
Publish Year,1994
Cited Num,229
Title,Prospective study of endogenous tissue plasminogen activator and risk of stroke


Publish Journal,jama
Publish Year,1994
Cited Num,226
Title,Association of Moderate Alcohol Consumption and Plasma Concentration of Endogenous Tissue-Type Plasminogen Activator


Publish Journal,ann intern med
Publish Year,1999
Cited Num,225
Title,Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks?


Publish Journal,lancet
Publish Year,1997
Cited Num,219
Title,PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.


Publish Journal,circulation
Publish Year,1997
Cited Num,217
Title,Interrelation of Hyperhomocyst(e)inemia, Factor V Leiden, and Risk of Future Venous Thromboembolism


Publish Journal,circulation
Publish Year,1990
Cited Num,210
Title,Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians.


Publish Journal,lancet
Publish Year,2013
Cited Num,201
Title,Statins: new American guidelines for prevention of cardiovascular disease


Publish Journal,amer j hum genet
Publish Year,2008
Cited Num,193
Title,Loci Related to Metabolic-Syndrome Pathways Including LEPR,HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women's Genome Health Study


Publish Journal,j amer coll cardiol
Publish Year,2007
Cited Num,176
Title,C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk


Publish Journal,circulation
Publish Year,1995
Cited Num,173
Title,Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.


Publish Journal,jama
Publish Year,1999
Cited Num,173
Title,Homocysteine and risk of cardiovascular disease among postmenopausal women


Publish Journal,circulation
Publish Year,1999
Cited Num,170
Title,G20210A Mutation in Prothrombin Gene and Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in a Large Cohort of US Men


Publish Journal,circulation
Publish Year,1999
Cited Num,165
Title,Prospective Study of Chlamydia pneumoniae IgG Seropositivity and Risks of Future Myocardial Infarction


Publish Journal,amer heart j
Publish Year,2004
Cited Num,164
Title,High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit


Publish Journal,circulation
Publish Year,2003
Cited Num,163
Title,C-Reactive Protein A Simple Test to Help Predict Risk of Heart Attack and Stroke


Publish Journal,lancet
Publish Year,2012
Cited Num,160
Title,Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention


Publish Journal,amer j cardiol
Publish Year,2003
Cited Num,159
Title,High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention


Publish Journal,jama
Publish Year,2006
Cited Num,155
Title,Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005


Publish Journal,j thromb haemost
Publish Year,2009
Cited Num,154
Title,Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)


Publish Journal,circulation
Publish Year,1994
Cited Num,151
Title,Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.


Publish Journal,ann intern med
Publish Year,1998
Cited Num,145
Title,Factor V Leiden Mutation as a Risk Factor for Recurrent Pregnancy Loss


Publish Journal,nutr rev
Publish Year,2007
Cited Num,144
Title,Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity


Publish Journal,circulation
Publish Year,1997
Cited Num,140
Title,Arterial and Venous Thrombosis Is Not Associated With the 4G/5G Polymorphism in the Promoter of the Plasminogen Activator Inhibitor Gene in a Large Cohort of US Men


Publish Journal,j amer coll cardiol
Publish Year,2005
Cited Num,130
Title,Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.


Publish Journal,circulation
Publish Year,1998
Cited Num,125
Title,Prospective Study of Herpes Simplex Virus, Cytomegalovirus, and the Risk of Future Myocardial Infarction and Stroke


Publish Journal,lancet
Publish Year,2010
Cited Num,121
Title,HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial


Publish Journal,j periodontol
Publish Year,2008
Cited Num,119
Title,Inflammation, C-Reactive Protein, and Atherothrombosis


Publish Journal,ann intern med
Publish Year,1991
Cited Num,115
Title,Low-Dose Aspirin Therapy for Chronic Stable Angina: A Randomized, Placebo-Controlled Clinical Trial


Publish Journal,cardiol clin
Publish Year,2003
Cited Num,109
Title,C-reactive protein, inflammation, and coronary risk ☆


Publish Journal,j amer coll cardiol
Publish Year,2005
Cited Num,108
Title,Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l


Publish Journal,j amer coll cardiol
Publish Year,2010
Cited Num,103
Title,Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein : A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention–an Intervention Trial Evaluating Rosuvastatin) Trial


Publish Journal,clin chem
Publish Year,2008
Cited Num,102
Title,Rationale, Design, and Methodology of the Women’s Genome Health Study: A Genome-Wide Association Study of More Than 25 000 Initially Healthy American Women


Publish Journal,hypertension
Publish Year,2006
Cited Num,100
Title,Valsartan, Blood Pressure Reduction, and C-Reactive Protein Primary Report of the Val-MARC Trial


Publish Journal,circulation
Publish Year,2003
Cited Num,99
Title,Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.


Publish Journal,circulation
Publish Year,2002
Cited Num,98
Title,On Evolutionary Biology, Inflammation, Infection, and the Causes of Atherosclerosis


Publish Journal,ann intern med
Publish Year,1999
Cited Num,96
Title,Baseline IgG Antibody Titers to Chlamydia pneumoniae, Helicobacter pylori, Herpes Simplex Virus, and Cytomegalovirus and the Risk for Cardiovascular Disease in Women


Publish Journal,lancet
Publish Year,2001
Cited Num,96
Title,Role of inflammatory biomarkers in prediction of coronary heart disease


Publish Journal,circulation
Publish Year,2012
Cited Num,91
Title,Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen A Phase IIb Randomized, Placebo-Controlled Trial


Publish Journal,jama
Publish Year,1995
Cited Num,90
Title,Plasma Concentration of Lipoprotein(a) and the Risk of Future Stroke


Publish Journal,circ cardiovasc genet
Publish Year,2009
Cited Num,89
Title,Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction Genomewide Analysis Among 18 245 Initially Healthy Women From the Women’s Genome Health Study


Publish Journal,circulation
Publish Year,1998
Cited Num,88
Title,Inflammation, Infection, and Cardiovascular Risk How Good Is the Clinical Evidence?


Publish Journal,amer j cardiol
Publish Year,2007
Cited Num,87
Title,Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein


Publish Journal,arterioscler thromb vasc biol
Publish Year,2003
Cited Num,85
Title,Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction.


Publish Journal,ann intern med
Publish Year,1997
Cited Num,84
Title,Age-Specific Incidence Rates of Venous Thromboembolism among Heterozygous Carriers of Factor V Leiden Mutation


Publish Journal,eur heart j
Publish Year,2014
Cited Num,83
Title,Anti-inflammatory therapies for cardiovascular disease


Publish Year,1998
Cited Num,78
Title,Prospective studies of C-reactive protein as a risk factor for cardiovascular disease.


Publish Journal,gastroenterology
Publish Year,1985
Cited Num,76
Title,Hepatic Venocclusive Disease Associated With the Consumption of Pyrrolizidine Containing Dietary Supplements


Publish Journal,clin chem
Publish Year,2009
Cited Num,71
Title,C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease


Publish Year,2007
Cited Num,70
Title,Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women


Publish Journal,amer j cardiol
Publish Year,2010
Cited Num,70
Title,Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).


Publish Journal,n engl j med
Publish Year,2004
Cited Num,68
Title,C-reactive protein and coronary heart disease.


Publish Journal,circ cardiovasc qual outcomes
Publish Year,2009
Cited Num,68
Title,Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)


Publish Year,2000
Cited Num,61
Title,Novel risk factors and markers for coronary disease.


Publish Journal,eur heart j
Publish Year,1998
Cited Num,57
Title,C-reactive protein and risks of future myocardial infarction and thrombotic stroke.


Publish Journal,clin chem
Publish Year,2008
Cited Num,54
Title,Fasting versus Nonfasting Triglycerides and the Prediction of Cardiovascular Risk: Do We Need to Revisit the Oral Triglyceride Tolerance Test?


Publish Journal,current atherosclerosis reports
Publish Year,2003
Cited Num,53
Title,C-reactive protein and risk of cardiovascular disease: Evidence and clinical application


Publish Journal,current atherosclerosis reports
Publish Year,2013
Cited Num,53
Title,Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?


Publish Journal,ann intern med
Publish Year,2001
Cited Num,43
Title,A Prospective Study of Helicobacter pylori Seropositivity and the Risk for Future Myocardial Infarction among Socioeconomically Similar U.S. Men


Publish Journal,circulation
Publish Year,2002
Cited Num,42
Title,Inflammatory Biomarkers, Statins, and the Risk of Stroke Cracking a Clinical Conundrum


Publish Journal,eur heart j
Publish Year,2001
Cited Num,41
Title,Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial.


Publish Journal,circulation
Publish Year,1992
Cited Num,39
Title,Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.


Publish Journal,circulation
Publish Year,2002
Cited Num,39
Title,Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events


Publish Journal,lancet
Publish Year,2014
Cited Num,38
Title,LDL cholesterol: controversies and future therapeutic directions


Publish Journal,amer heart j
Publish Year,1991
Cited Num,37
Title,The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: Clinical evidence from the physicians' health study


Publish Journal,ann intern med
Publish Year,1993
Cited Num,36
Title,Large-Scale Trials of Thrombolytic Therapy for Acute Myocardial Infarction: GISSI-2, ISIS-3, and GUSTO-1


Publish Journal,n engl j med
Publish Year,2007
Cited Num,35
Title,Biomarkers for prediction of cardiovascular events.


Publish Journal,lancet
Publish Year,2014
Cited Num,35
Title,Refining the American guidelines for prevention of cardiovascular disease – Authors' reply


Publish Journal,arterioscler thromb vasc biol
Publish Year,1997
Cited Num,33
Title,Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.


Publish Journal,texas heart institute journal
Publish Year,2005
Cited Num,33
Title,C-Reactive Protein, Inflammation, and Cardiovascular Disease: Clinical Update


Publish Journal,circ cardiovasc qual outcomes
Publish Year,2009
Cited Num,33
Title,The JUPITER Trial Results, Controversies, and Implications for Prevention


Publish Journal,clin cardiol
Publish Year,2003
Cited Num,32
Title,Connecting the role of C‐reactive protein and statins in cardiovascular disease


Publish Journal,lancet
Publish Year,1993
Cited Num,31
Title,Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction


Publish Journal,lancet
Publish Year,1999
Cited Num,29
Title,Assessment of genetic markers for coronary thrombosis: promise and precaution


Publish Journal,jama
Publish Year,2013
Cited Num,29
Title,A Trial-Based Approach to Statin Guidelines


Publish Journal,amer heart j
Publish Year,1991
Cited Num,27
Title,Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease


Publish Journal,amer j cardiol
Publish Year,1992
Cited Num,26
Title,Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction


Publish Journal,circulation
Publish Year,2005
Cited Num,26
Title,Should Age and Time Be Eliminated From Cardiovascular Risk Prediction Models? Rationale for the Creation of a New National Risk Detection Program


Publish Journal,circ cardiovasc genet
Publish Year,2011
Cited Num,26
Title,Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.


Publish Journal,j cardiovasc risk
Publish Year,1996
Cited Num,25
Title,Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women


Publish Journal,clin chem
Publish Year,2012
Cited Num,24
Title,Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial


Publish Journal,ann intern med
Publish Year,1994
Cited Num,22
Title,A Response to “Holding GUSTO Up to the Light”


Publish Journal,circulation
Publish Year,1991
Cited Num,21
Title,Hemostatic risk factors for coronary heart disease.


Publish Journal,arch environ health
Publish Year,1987
Cited Num,20
Title,Toxic effects of herbal teas.


Publish Journal,amer j med
Publish Year,1989
Cited Num,19
Title,Streptokinase therapy and cholesterol embolization


Publish Journal,vasc med
Publish Year,1998
Cited Num,19
Title,Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial


Publish Journal,circ cardiovasc qual outcomes
Publish Year,2010
Cited Num,19
Title,Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for “Intermediate Risk”


Publish Journal,clin chem
Publish Year,2008
Cited Num,18
Title,High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care


Publish Journal,amer j cardiol
Publish Year,2010
Cited Num,17
Title,The JUPITER Trial: Responding to the Critics


Publish Journal,american heart hospital journal
Publish Year,2004
Cited Num,16
Title,Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice.


Publish Journal,j thromb haemost
Publish Year,2004
Cited Num,16
Title,Long‐term low‐dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes


Publish Journal,arthritis rheumatism
Publish Year,2009
Cited Num,16
Title,Should patients with rheumatoid arthritis receive statin therapy


Publish Journal,eur heart j
Publish Year,2013
Cited Num,16
Title,C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care


Publish Journal,pathophysiol haemost thromb
Publish Year,1997
Cited Num,15
Title,Intrinsic Fibrinolytic Capacity and Systemic Inflammation: Novel Risk Factors for Arterial Thrombotic Disease


Publish Journal,n engl j med
Publish Year,2003
Cited Num,15
Title,Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.


Publish Journal,arterioscler thromb vasc biol
Publish Year,2008
Cited Num,15
Title,The Time for Cardiovascular Inflammation Reduction Trials Has Arrived How Low to Go for hsCRP


Publish Journal,amer j cardiol
Publish Year,2009
Cited Num,15
Title,The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications


Publish Journal,j thromb thrombolysis
Publish Year,1994
Cited Num,14
Title,Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.


Publish Journal,current cardiology reports
Publish Year,2000
Cited Num,14
Title,Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation.


Publish Journal,circulation
Publish Year,1991
Cited Num,13
Title,Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy.


Publish Journal,american family physician
Publish Year,1989
Cited Num,12
Title,Health hazards of unusual herbal teas.


Publish Journal,clinical cornerstone
Publish Year,2002
Cited Num,12
Title,Inherited risk factors for venous thromboembolism: implications for clinical practice.


Publish Journal,eur heart j
Publish Year,2014
Cited Num,12
Title,Targeting inflammatory pathways for the treatment of cardiovascular disease


Publish Journal,curr opin lipidol
Publish Year,1992
Cited Num,11
Title,An epidemiologic assessment of thrombotic risk factors for cardiovascular disease


Publish Journal,arterioscler thromb vasc biol
Publish Year,1993
Cited Num,11
Title,A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100.


Publish Journal,eur heart j
Publish Year,2010
Cited Num,11
Title,Psoriasis, inflammation, and vascular risk: a problem more than skin deep?


Publish Journal,circ cardiovasc genet
Publish Year,2011
Cited Num,11
Title,KIF6 Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention


Publish Year,2009
Cited Num,10
Title,Obesity and Risk of Death


Publish Year,2013
Cited Num,10
Title,Closing the Loop on Inflammation and Atherothrombosis: Why Perform the Cirt and Cantos Trials?


Publish Journal,circ res
Publish Year,2014
Cited Num,10
Title,Inflammation, C-Reactive Protein, and Cardiovascular Disease Moving Past the Marker Versus Mediator Debate


Publish Journal,arch intern med
Publish Year,2006
Cited Num,9
Title,C-Reactive Protein and Cardiovascular Risk in the Framingham Study


Publish Journal,amer j med
Publish Year,1989
Cited Num,8
Title,Hepatotoxicity due to comfrey herb tea


Publish Journal,lancet
Publish Year,2009
Cited Num,8
Title,Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin


Publish Journal,chronobiol int
Publish Year,2010
Cited Num,8
Title,Aspirin, Platelet Aggregation, and the Circadian Variation of Acute Thrombotic Events


Publish Journal,circulation
Publish Year,1996
Cited Num,7
Title,Age and Thrombolytic Therapy


Publish Journal,acc current journal review
Publish Year,2005
Cited Num,7
Title,Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women


Publish Journal,jama
Publish Year,2006
Cited Num,7
Title,Use of aspirin as primary prevention of cardiovascular events.


Publish Journal,current atherosclerosis reports
Publish Year,2009
Cited Num,7
Title,Moving toward new statin guidelines in a post-JUPITER world: Principles to consider


Publish Journal,j amer coll cardiol
Publish Year,2010
Cited Num,7
Title,Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein


Publish Year,2012
Cited Num,7
Title,Hyperlipidemia as an instigator of inflammation: inaugurating new approaches to vascular prevention.


Publish Journal,ann intern med
Publish Year,2015
Cited Num,7
Title,Comparing Cardiovascular Risk Prediction Scores


Publish Journal,amer j clin pathol
Publish Year,1990
Cited Num,6
Title,False positive mononucleosis screening test results associated with Klebsiella hepatic abscess.


Publish Journal,ann epidemiol
Publish Year,1994
Cited Num,6
Title,Lipoprotein(a) and risks of cardiovascular disease


Publish Journal,climacteric
Publish Year,2009
Cited Num,6
Title,Homocysteine and risk of cardiovascular disease among postmenopausal women


Publish Journal,clin chem
Publish Year,2010
Cited Num,6
Title,Establishing a clinical basis for hsCRP in the prevention and treatment of cardiovascular disease.


Publish Journal,clin chem
Publish Year,2010
Cited Num,6
Title,Statin Therapy for Low-LDL, High-hsCRP Patients: From JUPITER to CORONA


Publish Journal,trend cardiovasc med
Publish Year,1995
Cited Num,5
Title,An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk


Publish Journal,j thromb thrombolysis
Publish Year,1999
Cited Num,5
Title,Pathogenesis and pathology of coronary heart disease syndromes.


Publish Journal,n engl j med
Publish Year,2001
Cited Num,5
Title,Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.


Publish Journal,lancet
Publish Year,2010
Cited Num,5
Title,JUPITER, rosuvastatin, and the European Medicines Agency


Publish Journal,texas heart institute journal
Publish Year,2010
Cited Num,5
Title,Inflammation, high-sensitivity C-reactive protein, and vascular protection.


Publish Journal,lancet
Publish Year,2011
Cited Num,5
Title,C-reactive protein in the Heart Protection Study


Publish Journal,j thromb thrombolysis
Publish Year,1995
Cited Num,4
Title,Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors


Publish Journal,jama
Publish Year,2006
Cited Num,4
Title,Incomplete Financial Disclosure for Study of Funding and Outcomes in Major Cardiovascular Trials


Publish Journal,clin chem
Publish Year,2009
Cited Num,4
Title,Myocardial Infarction in a 72-Year-Old Woman with Low LDL-C and Increased hsCRP: Implications for Statin Therapy


Publish Journal,clin trials
Publish Year,2011
Cited Num,4
Title,A tale of three labels: translating the JUPITER trial data into regulatory claims


Publish Journal,ann intern med
Publish Year,1994
Cited Num,3
Title,More on the GUSTO Trial


Publish Journal,j thromb thrombolysis
Publish Year,1995
Cited Num,3
Title,Direct comparison of aspirin plus hirudin aspirin plus heparin, and aspirin alone among 12,000 patients with acute myocardial infarction not receiving thrombolysis: Rationale and design of the First American Study of Infarct Survival (ASIS-1)


Publish Journal,current cardiology reports
Publish Year,1999
Cited Num,3
Title,Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis


Publish Journal,jama
Publish Year,2007
Cited Num,3
Title,Algorithms for Assessing Cardiovascular Risk in Women—Reply


Publish Journal,circulation
Publish Year,2012
Cited Num,3
Title,Lipoprotein(a), Ethnicity, and Cardiovascular Risk Erasing a Paradox and Filling a Clinical Gap


Publish Journal,lancet
Publish Year,2012
Cited Num,3
Title,Coronary artery calcium for guiding statin treatment


Publish Journal,jama
Publish Year,2014
Cited Num,3
Title,Formulation of treatment recommendations for statins--reply.


Publish Journal,eur heart j
Publish Year,2015
Cited Num,3
Title,Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events


Publish Journal,eur heart j
Publish Year,2016
Cited Num,3
Title,Per cent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents


Publish Journal,fibrinolysis
Publish Year,1997
Cited Num,2
Title,Endogenous fibrinolytic function and risks of future myocardial infarction and stroke: observations from the Physicians' Health Study


Publish Journal,acc current journal review
Publish Year,2001
Cited Num,2
Title,Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease


Publish Journal,metab syndr relat disord
Publish Year,2010
Cited Num,2
Title,Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution


Publish Journal,arch intern med
Publish Year,2011
Cited Num,2
Title,Coronary Artery Calcium Scanning in Primary Prevention: A Conversation With Cardiology Fellows


Publish Journal,circ cardiovasc imaging
Publish Year,2011
Cited Num,2
Title,High-Sensitivity C-Reactive Protein, Vascular Imaging, and Vulnerable Plaque More Evidence to Support Trials of Antiinflammatory Therapy for Cardiovascular Risk Reduction


Publish Year,2014
Cited Num,2
Title,Plasma Levels of the Proinflammatory Chitin-Binding Glycoprotein YKL-40, Variation in the Chitinase 3-Like 1 Gene (CHI3L1), and Incident Cardiovascular Events


Publish Journal,j amer coll cardiol
Publish Year,2015
Cited Num,2
Title,A Proposal to Incorporate Trial Data Into a Hybrid ACC/AHA Algorithm for the Allocation of Statin Therapy in Primary Prevention


Publish Journal,circ res
Publish Year,2016
Cited Num,2
Title,From C-Reactive Protein to Interleukin-6 to Interleukin-1 Moving Upstream To Identify Novel Targets for Atheroprotection


Publish Journal,j pediat
Publish Year,1989
Cited Num,1
Title,Hepatic veno-occlusive disease and herbal teas


Publish Year,2002
Cited Num,1
Title,Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of


Publish Journal,jama
Publish Year,2005
Cited Num,1
Title,Risk Factors for Cardiovascular Disease in Women—Reply


Publish Journal,lancet
Publish Year,2009
Cited Num,1
Title,Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial – Authors' reply


Publish Journal,lancet
Publish Year,2010
Cited Num,1
Title,HDL cholesterol and residual risk of first cardiovascular events – Authors' reply


Publish Journal,the cardiology
Publish Year,2012
Cited Num,1
Title,Increased Mortality Rates in the JUPITER Trial


Publish Journal,circulation
Publish Year,2013
Cited Num,1
Title,Expanding Options for Scientific Publication Is More Always Better


Publish Journal,eur heart j
Publish Year,2016
Cited Num,1
Title,Monoclonal antibodies targeting PCSK9 and the search for prolonged duration of effect


Publish Journal,j ethnopharmacol
Publish Year,1988
Cited Num,0
Title,Toxic effects of herbal teas


Publish Journal,j amer coll cardiol
Publish Year,1990
Cited Num,0
Title,Time to presentation for acute mi in the us physicians' health study


Publish Journal,ann thorac surg
Publish Year,1991
Cited Num,0
Title,Surgical management of carcinoid heart disease


Publish Journal,n engl j med
Publish Year,1993
Cited Num,0
Title,Book Review Prognosis and Risk Assessment in Cardiovascular Disease Edited by Amar S. Kapoor and Bramah N. Singh. 578 pp., illustrated. New York, Churchill Livingstone, 1993. $79.95. 0-443-08768-7


Publish Journal,biomed pharmacotherapy
Publish Year,1993
Cited Num,0
Title,Endogenous tissue-type plasminogen activator and myocardial infarction


Publish Journal,jama
Publish Year,1994
Cited Num,0
Title,Lipoprotein(a) and Risk of Myocardial Infarction-Reply


Publish Journal,jama
Publish Year,1995
Cited Num,0
Title,Lipoprotein(a) Concentration and Risk of Atherothrombotic Disease-Reply


Publish Journal,jama
Publish Year,1995
Cited Num,0
Title,Alcohol Consumption and Tissue-Type Plasminogen Activator-Reply


Publish Journal,ann intern med
Publish Year,1996
Cited Num,0
Title,Megatrials for Clinical Decision Making


Publish Journal,gender development
Publish Year,1997
Cited Num,0
Title,Inflammation, Aspirin, and Cardiovascular Disease


Publish Year,1997
Cited Num,0
Title,allele in the 330 Japanese people in our study suggests that this allele does not have an important role in the risk of cardiovascular events in Japan.


Publish Journal,lancet
Publish Year,1997
Cited Num,0
Title,PIA1/A2 polymorphism of platelet glycoprotein Illa and risk of cardiovascular disease


Publish Journal,vasc med
Publish Year,1998
Cited Num,0
Title,Thrombosis and Thromboembolism: New Strategies for Improved Patient Care


Publish Year,1998
Cited Num,0
Title,Means of ascertaining an individual' s risk profile for atherosclerotic disease


Publish Year,1999
Cited Num,0
Title,Activated Protein C Resistance, Factor V Leiden, and Venous Thromboembolism


Publish Journal,obstet gynecol surv
Publish Year,2000
Cited Num,0
Title,Factor V Leiden Mutation As a Risk Factor for Recurrent Pregnancy Loss


Publish Year,2001
Cited Num,0
Title,Inflammatory markers for detection and prevention of diabetes mellitus


Publish Journal,n engl j med
Publish Year,2002
Cited Num,0
Title,Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.


Publish Journal,obstet gynecol surv
Publish Year,2003
Cited Num,0
Title,Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events


Publish Year,2003
Cited Num,0
Title,La anticoagulación de baja intensidad y larga duración es eficaz en la prevención de la tromboembolia venosa recurrente


Publish Journal,n engl j med
Publish Year,2003
Cited Num,0
Title,Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism


Publish Year,2004
Cited Num,0
Title,Method for preventing recurring venous thromboembolism using long-term low-intensity warfarin


Publish Year,2005
Cited Num,0
Title,ASA prevents stroke, not MI, in women.


Publish Journal,j vasc surg
Publish Year,2005
Cited Num,0
Title,C-reactive protein levels and outcomes after statin therapy


Publish Journal,j vasc surg
Publish Year,2005
Cited Num,0
Title,A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women


Publish Journal,obstet gynecol surv
Publish Year,2005
Cited Num,0
Title,A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women


Publish Journal,n engl j med
Publish Year,2005
Cited Num,0
Title,A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.


Publish Year,2005
Cited Num,0
Title,USE OF AN AGENT FOR LOWERING THE RISK OF CARDIOVASCULAR DISEASE


Publish Year,2005
Cited Num,0
Title,Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease


Publish Year,2007
Cited Num,0
Title,Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases


Publish Journal,circulation
Publish Year,2007
Cited Num,0
Title,Letter by Ridker and Everett Regarding Article, “The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?”


Publish Journal,circulation
Publish Year,2008
Cited Num,0
Title,Abstract 5100: C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men


Publish Year,2009
Cited Num,0
Title,Publishing Title: Rosuvastatin in the Prevention of Stroke Among Men and Women with Elevated Levels of C- Reactive Protein: The JUPITER Trial


Publish Journal,atheroscler suppl
Publish Year,2009
Cited Num,0
Title,Abstract: S6-27 USING NOVEL RISK FACTORS IN CLINICAL TRIALS


Publish Journal,obstet gynecol surv
Publish Year,2009
Cited Num,0
Title,Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein


Publish Journal,j vasc surg
Publish Year,2009
Cited Num,0
Title,Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein


Publish Journal,obstet gynecol surv
Publish Year,2009
Cited Num,0
Title,Reduction in C-Reactive Protein and Low-Density Lipoprotein Cholesterol and Cardiovascular Event Rates After Initiation of Rosuvastatin: A Prospective Study of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin Trial


Publish Journal,j amer coll cardiol
Publish Year,2010
Cited Num,0
Title,EFFICACY OF ROSUVASTATIN AMONG MEN AND WOMEN WITH CHRONIC KIDNEY DISEASE AND ELEVATED HSCRP: THE JUPITER TRIAL


Publish Journal,j amer coll cardiol
Publish Year,2010
Cited Num,0
Title,EFFICACY OF ROSUVASTATIN IN PRIMARY PREVENTION ACCORDING TO BASELINE LEVELS OF HSCRP IN THE JUPITER TRIAL


Publish Journal,am j manag care
Publish Year,2010
Cited Num,0
Title,Statin therapy for elevated hsCRP: what are the public health implications?


Publish Year,2010
Cited Num,0
Title,Missing centenarians in Japan: a new ageism


Publish Year,2010
Cited Num,0
Title,aspirin in a randomized trial of physicians Circadian variation of acute myocardial infarction and the effect of low-dose


Publish Year,2010
Cited Num,0
Title,Screening as Predictors of Peripheral Arterial Disease Homocysteine, Lipoprotein(a), and Standard Cholesterol Comparison of C-Reactive Protein, Fibrinogen, Novel Risk Factors for Systemic Atherosclerosis: A


Publish Year,2011
Cited Num,0
Title,POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT


Publish Journal,j amer coll cardiol
Publish Year,2011
Cited Num,0
Title,KIF6 POLYMORPHISM AND THE EFFICACY OF STATIN THERAPY IN PRIMARY PREVENTION: DATA FROM THE JUPITER TRIAL


Publish Journal,j vasc surg
Publish Year,2012
Cited Num,0
Title,Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: An Analysis From the JUPITER Trial


Publish Journal,j amer coll cardiol
Publish Year,2012
Cited Num,0
Title,EFFECTS OF INTERLEUKIN-1β INHIBITION WITH CANAKINUMAB ON IL-6, FIBRINOGEN, AND HSCRP: A RANDOMIZED PLACEBO CONTROLLED TRIAL


Publish Year,2012
Cited Num,0
Title,Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes


Publish Journal,j amer coll cardiol
Publish Year,2016
Cited Num,0
Title,A Test in Context : High-Sensitivity C-Reactive Protein


Publish Journal,amer heart j
Publish Year,2016
Cited Num,0
Title,Evaluating Bococizumab, a Monoclonal Antibody to PCSK9, on Lipid Levels and Clinical Events in Broad Patient Groups With and Without Prior Cardiovascular Events: Rationale and Design of the SPIRE Lipid Lowering and SPIRE Cardiovascular Outcomes Trials


Publish Journal,eur heart j
Publish Year,2016
Cited Num,0
Title,Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

academic_age,35
